A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort

被引：0
|
作者：
Yuan, Li
Shu, Pei
Li, Xiaoyu
Li, Guiling
Zhang, Keqiang
Lai, Lin
Hong, Jinsheng
Huang, Chu-Ying
Wang, Yongsheng
Xie, Hui
Zheng, Li
Zhou, Qi
机构：
[1] Chongqing Univ Canc Hosp, Chongqing, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Med Prod Adm Key Lab Clin Res & Evaluat Inno, Clin Trial Ctr,State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[4] Hunan Canc Hosp, Changsha, Peoples R China
[5] Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Dept Abdominal Oncol, Enshi, Peoples R China
[6] Fujian Med Univ, Dept Radiotherapy, Ctr Canc, Affiliated Hosp 1, Fuzhou, Peoples R China
[7] Hubei Selenium & Human Hlth Inst, Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Enshi, Peoples R China
[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[9] Antengene Corp, Dept Clin Res & Dev, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5509
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid fumors.
    Cohen, R. B.
    Janne, P. A.
    Engelman, J. A.
    Martinez, P.
    Nishida, Y.
    Gendreau, S.
    Wu, B.
    Felip, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Combination of TORC1/2 and MEK kinase inhibitors in colorectal cancer models
    Garcia-Garcia, Celina
    Serra, Violeta
    Scaltriti, Maurizio
    Ibrahim, Yasir
    Guzman, Marta
    Jessen, Katti
    Liu, Yi
    Rommel, Christian
    Tabernero, Josep
    Baselga, Jose
    CANCER RESEARCH, 2011, 71
  • [43] Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs
    Wei, Bih-Rong
    Peer, Cody J.
    Richardson, William J.
    Hewitt, Stephen M.
    Figg, William D.
    Simpson, R. Mark
    FRONTIERS IN VETERINARY SCIENCE, 2022, 9
  • [44] Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
    Parikh, Aparna Raj
    Radojcic, Vedran
    Clancy, Myles
    Brouwer, Susan
    Kushwaha, Shaliny
    Huang, Yifan
    Gabrail, Nashat
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS227 - TPS227
  • [45] AZD8055, a combined TORC1/TORC2 inhibitor regulates Mycn protein expression and prevents neuroblastoma growth in vitro and in vivo
    Vaughan, Lynsey S.
    Barker, Karen
    Webber, Hannah
    Yann Jamin
    Robinson, Simon
    Guichard, Sylvie
    Chesler, Louis
    CANCER RESEARCH, 2011, 71
  • [46] A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors
    Scott, Susan C.
    Farago, Anna
    Lai, W. Victoria
    Zahurak, Marianna
    Rudek, Michelle A.
    Murray, Judy
    Carducci, Michael A.
    Uziel, Tamar
    Takebe, Naoko
    Gore, Steven D.
    Rudin, Charles M.
    Hann, Christine L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [47] Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.
    Paik, Paul K.
    Qeriqi, Besnik
    Ahn, Linda Su Hyun
    Ginsberg, Michelle S.
    Tandon, Nidhi
    McFarland, Daniel
    Doyle, L. Austin
    de Stanchina, Elisa
    Rudin, Charles M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228
    Paik, P.
    Ahn, L.
    Ginsberg, M.
    Mcfarland, D.
    Doyle, L.
    Rudin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S816 - S816
  • [49] A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
    Olszanski, Anthony J.
    Middleton, Mark R.
    Bahleda, Rastilav
    Heist, Rebecca Suk
    Rangachari, Lakshmi
    Zhou, Xiaofei
    Bozon, Viviana
    Kneissl, Michelle
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity
    Rubens, Jeffrey A.
    Wang, Sabrina Z.
    Price, Antoinette
    Weingart, Melanie F.
    Allen, Sariah J.
    Orr, Brent A.
    Eberhart, Charles G.
    Raabe, Eric H.
    NEURO-ONCOLOGY, 2017, 19 (10) : 1361 - 1371
12345